Interleukin 28 and Interleukin 29 May Have Therapeutic Value Against Hepatitis Viruses in Humans

[Guest guest]

Interleukin 28 and Interleukin 29 May Have Therapeutic Value Against

Hepatitis Viruses in Humans

By Mark , MD

Interleukin 28 and interleukin 29 (IL-28 and IL-29) are a recently

discovered

family of novel class II cytokines distantly related to interferon alpha and

interleukin 10 (IL-10).

IL-10 uses a newly identified class II cytokine receptor IL-28R, and I-L28

has

previously been shown to have antiviral activity against

encephalomyocarditis

virus.

IL-28 and IL-29 were tested for antiviral activity against hepatitis B virus

antiviral activity using Hep G2 WT10 cells which contain stable integration

of the HBV genome.

Because of the lack of an efficient model system to replicate HCV, a

surrogate

viral system from the flavaviridae family- bovine viral diarrhea virus- was

evaluated for potential IL-28 and IL-29 activity against hepatitis C.

IL-28 and IL-29 inhibited HBV replication in Hep G2 WT10 cells with an IC50

of

less than 0.032 micro grams/ml. IL-28 and IL-29 also inhibited BVDV

dependant

cell death, with an IC50 of 0.02 and 0.19 respectively.

IL-28 and IL-29 may therefore have therapeutic value against hepatitis

viruses

in human patients.

01/12/04

Source

HEP DART 2003. December 14-18, 2003. Kauai, Hawaii

[Guest guest]

Interleukin 28 and Interleukin 29 May Have Therapeutic Value Against

Hepatitis Viruses in Humans

By Mark , MD

Interleukin 28 and interleukin 29 (IL-28 and IL-29) are a recently

discovered

family of novel class II cytokines distantly related to interferon alpha and

interleukin 10 (IL-10).

IL-10 uses a newly identified class II cytokine receptor IL-28R, and I-L28

has

previously been shown to have antiviral activity against

encephalomyocarditis

virus.

IL-28 and IL-29 were tested for antiviral activity against hepatitis B virus

antiviral activity using Hep G2 WT10 cells which contain stable integration

of the HBV genome.

Because of the lack of an efficient model system to replicate HCV, a

surrogate

viral system from the flavaviridae family- bovine viral diarrhea virus- was

evaluated for potential IL-28 and IL-29 activity against hepatitis C.

IL-28 and IL-29 inhibited HBV replication in Hep G2 WT10 cells with an IC50

of

less than 0.032 micro grams/ml. IL-28 and IL-29 also inhibited BVDV

dependant

cell death, with an IC50 of 0.02 and 0.19 respectively.

IL-28 and IL-29 may therefore have therapeutic value against hepatitis

viruses

in human patients.

01/12/04

Source

HEP DART 2003. December 14-18, 2003. Kauai, Hawaii

[Guest guest]

Interleukin 28 and Interleukin 29 May Have Therapeutic Value Against

Hepatitis Viruses in Humans

By Mark , MD

Interleukin 28 and interleukin 29 (IL-28 and IL-29) are a recently

discovered

family of novel class II cytokines distantly related to interferon alpha and

interleukin 10 (IL-10).

IL-10 uses a newly identified class II cytokine receptor IL-28R, and I-L28

has

previously been shown to have antiviral activity against

encephalomyocarditis

virus.

IL-28 and IL-29 were tested for antiviral activity against hepatitis B virus

antiviral activity using Hep G2 WT10 cells which contain stable integration

of the HBV genome.

Because of the lack of an efficient model system to replicate HCV, a

surrogate

viral system from the flavaviridae family- bovine viral diarrhea virus- was

evaluated for potential IL-28 and IL-29 activity against hepatitis C.

IL-28 and IL-29 inhibited HBV replication in Hep G2 WT10 cells with an IC50

of

less than 0.032 micro grams/ml. IL-28 and IL-29 also inhibited BVDV

dependant

cell death, with an IC50 of 0.02 and 0.19 respectively.

IL-28 and IL-29 may therefore have therapeutic value against hepatitis

viruses

in human patients.

01/12/04

Source

HEP DART 2003. December 14-18, 2003. Kauai, Hawaii

[Guest guest]

Interleukin 28 and Interleukin 29 May Have Therapeutic Value Against

Hepatitis Viruses in Humans

By Mark , MD

Interleukin 28 and interleukin 29 (IL-28 and IL-29) are a recently

discovered

family of novel class II cytokines distantly related to interferon alpha and

interleukin 10 (IL-10).

IL-10 uses a newly identified class II cytokine receptor IL-28R, and I-L28

has

previously been shown to have antiviral activity against

encephalomyocarditis

virus.

IL-28 and IL-29 were tested for antiviral activity against hepatitis B virus

antiviral activity using Hep G2 WT10 cells which contain stable integration

of the HBV genome.

Because of the lack of an efficient model system to replicate HCV, a

surrogate

viral system from the flavaviridae family- bovine viral diarrhea virus- was

evaluated for potential IL-28 and IL-29 activity against hepatitis C.

IL-28 and IL-29 inhibited HBV replication in Hep G2 WT10 cells with an IC50

of

less than 0.032 micro grams/ml. IL-28 and IL-29 also inhibited BVDV

dependant

cell death, with an IC50 of 0.02 and 0.19 respectively.

IL-28 and IL-29 may therefore have therapeutic value against hepatitis

viruses

in human patients.

01/12/04

Source

HEP DART 2003. December 14-18, 2003. Kauai, Hawaii